Cryo-Cell International (NYSEAMERICAN:CCEL) Posts Earnings Results

Cryo-Cell International (NYSEAMERICAN:CCEL) announced its quarterly earnings results on Wednesday. The company reported $0.07 earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of $7.78 million for the quarter.

Cryo-Cell International Stock Up 5.3%

Shares of CCEL opened at $3.58 on Thursday. The firm has a market cap of $28.85 million, a price-to-earnings ratio of -10.85 and a beta of 0.49. The company’s fifty day moving average is $3.52 and its 200-day moving average is $3.45. Cryo-Cell International has a 12 month low of $2.72 and a 12 month high of $5.43.

Institutional Trading of Cryo-Cell International

A hedge fund recently bought a new position in Cryo-Cell International stock. Susquehanna International Group LLP purchased a new stake in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned 0.14% of Cryo-Cell International at the end of the most recent reporting period. 10.44% of the stock is currently owned by hedge funds and other institutional investors.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.